Seeing Is Believing
Currently out of the existing stock ratings of Steve Byrne, 35 are a SELL (19.89%), 81 are a BUY (46.02%), 60 are a HOLD (34.09%).
Analyst Steve Byrne, currently employed at BAML, carries an average stock price target met ratio of 68.56% that have a potential upside of 20.33% achieved within 234 days.
Steve Byrne’s has documented 522 price targets and ratings displayed on 32 stocks. The coverage is on Basic Materials, Consumer Defensive, Healthcare sectors.
Most recent stock forecast was given on CE, Celanese at 14-Jan-2025.
Analyst best performing recommendations are on PCRX (PACIRA PHARMACEUTICALS).
The best stock recommendation documented was for GPRE (GREEN PLAINS RENEWABLE ENERGY) at 10/24/2022. The price target of $35 was fulfilled within 17 days with a profit of $7.74 (28.39%) receiving and performance score of 16.7.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Time (Days) For PT To Be Met
Performance score
Hold
$105
$16.24 (18.30%)
$128
22 days ago
(07-Jan-2025)
20/23 (86.96%)
$15.02 (16.69%)
198
Hold
$103
$14.24 (16.04%)
$79
1 months 11 days ago
(18-Dec-2024)
18/25 (72%)
$7.69 (8.07%)
411
Buy
$127
$38.24 (43.08%)
$132
2 months 17 days ago
(12-Nov-2024)
21/32 (65.63%)
$22.31 (21.31%)
578
Buy
$133
$44.24 (49.84%)
$111
2 months 17 days ago
(12-Nov-2024)
21/31 (67.74%)
$28.31 (27.04%)
341
Buy
$170
$81.24 (91.53%)
$178
2 months 21 days ago
(08-Nov-2024)
7/17 (41.18%)
$69.16 (68.58%)
442
Which stock is Steve Byrne is most bullish on?
Which stock is Steve Byrne is most reserved on?
What Year was the first public recommendation made by Steve Byrne?